era

ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathyERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy

ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy

VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal…

13 hours ago